Research Analysts Offer Predictions for ARCT Q3 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Investment analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Arcturus Therapeutics in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn ($0.87) per share for the quarter, up from their prior forecast of ($0.94). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($3.46) EPS, FY2027 earnings at ($3.37) EPS, FY2028 earnings at ($3.31) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $5.63 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.16. The firm had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.

Other research analysts have also issued reports about the company. Wall Street Zen raised Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.25.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock opened at $7.60 on Thursday. Arcturus Therapeutics has a 1 year low of $5.50 and a 1 year high of $24.17. The firm has a market capitalization of $216.01 million, a PE ratio of -2.30 and a beta of 2.39. The stock has a fifty day moving average of $6.75 and a two-hundred day moving average of $7.39.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ARCT. Osaic Holdings Inc. lifted its holdings in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 738 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,567 shares during the last quarter. Strs Ohio bought a new stake in shares of Arcturus Therapeutics in the 1st quarter worth approximately $89,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Arcturus Therapeutics in the 4th quarter worth approximately $64,000. 94.54% of the stock is owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.